Percutaneous Transluminal Angioplasty

At 5 years, there was no link between a paclitaxel-coated balloon and excess mortality compared with percutaneous transluminal angioplasty in two studies of patients with peripheral artery disease.

In patients with calcified peripheral artery lesions treated with a drug-coated balloon, those who were pretreated with intravascular lithotripsy had better procedural outcomes than those pretreated with angioplasty, a speaker said at VIVA.

A paclitaxel-coated balloon was not associated with elevated mortality risk in patients who underwent revascularization for critical limb ischemia, according to 5-year data from the IN.PACT DEEP trial.

A drug-coated balloon was superior to percutaneous transluminal angioplasty at 1 year for primary patency and clinically driven target lesion revascularization in patients with de novo or restenotic arteriovenous fistula lesions, according to new data from the IN.PACT AV Access study.

A paclitaxel-coated balloon was safe and effective in patients with peripheral artery disease at 4 years and did not confer elevated mortality risk compared with percutaneous transluminal angioplasty, according to new data from the ILLUMENATE Pivotal trial.

LAS VEGAS — There were no significant differences in mortality at 5 years between patients with peripheral artery disease assigned a drug-eluting stent and those assigned a bare-metal stent or percutaneous transluminal angioplasty, according to new data presented at VIVA 19.